Navigation Links
Monogram Announces Third Quarter 2007 Financial Results
Date:10/24/2007

d our other products by the FDA, and activities expected to occur in connection with the Pfizer collaboration. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use a molecular diagnostic for patient selection for maraviroc or other HIV drugs; risks related to the implementation of the collaboration with Pfizer; risks related to our ability to recognize revenue from activities under the collaboration with Pfizer; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors, entry inhibitors or integrase inhibitors; the risk that our Trofile Assay may not be utilized for patient use with maraviroc and other CCR5 inhibitors; the risk that our VeraTag assays may not predict response to particular therapeutic agents; the risk that we may not be able to obtain additional cohorts of patient samples for additional VeraTag studies, our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will a
'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2
... 14 LI-COR Biosciences introduces a,new, novel protein ... Imaging system. The Odyssey Two-Color Protein Molecular Weight,Marker ... 800 nm channels of the,Odyssey System. The marker ... be used to visualize the progress of protein ...
... National Drug Control Policy to Moderate ... Bad Drugs, FRAZER, Pa., Oct. 14 ... embarking on a national educational,program designed to promote ... the importance of appropriate and responsible use of,prescription ...
... ProtoKinetix (OTC,Bulletin Board: PKTX), a biotech ... of patented anti-aging glycopeptides,(AAGPs(TM)), announced today that ... a division of National Financial Communications Corp.,(NFC), ... "ProtoKinetix, AAGP(TM) platform technology is ideal ...
Cached Biology Technology:LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker 2Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications 2ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 2ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 3
(Date:9/18/2014)... people are too stressed they are often grouchy, grumpy, ... Institute (BMI) at EPFL have just highlighted a fundamental ... and the loss of social skills and cognitive impairment. ... regulatory molecule in the brain. This was revealed by ... , Carmen Sandi,s team went to look for answers ...
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... student have designed a device based on a shorebird,s ... dew., The device could provide water in drought-stricken areas ... Luo, professor in the Mechanical & Aerospace Engineering Department, ... of Engineering department, published "Bioinspired Plate-Based Fog Collectors" in ... Applied Materials & Interfaces journal. ...
Breaking Biology News(10 mins):How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Shorebird's beak inspires UT Arlington research on water collection 2
... 23andMe, the leading personal genetics company, announces the ... Neil Rothstein as Vice President Marketing, and Jonathan ... company,s executive leadership team. As ... the company,s corporate communications, media relations and investor ...
... Oct. 17, 2012 Rising crime rates and ... increase monitoring and introduce reliable border control systems. ... criminal identification and automated immigration at all entry ... adoption in the government vertical across Asia-Pacific. ...
... 24, 2012  Aware, Inc. (NASDAQ: AWRE ), ... assurance products, today reported financial results for its third ... our DSL service assurance hardware business have been reported ... the shutdown of that business during the third quarter. ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4Aware, Inc. Reports Third Quarter 2012 Financial Results 2Aware, Inc. Reports Third Quarter 2012 Financial Results 3Aware, Inc. Reports Third Quarter 2012 Financial Results 4Aware, Inc. Reports Third Quarter 2012 Financial Results 5Aware, Inc. Reports Third Quarter 2012 Financial Results 6
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
... has a long and outstanding history ... Several years ago we became aware ... was being modified to inject Xenopus ... redesigning the microdispenser to eliminate any ...
...
... designed for sequencing inserts cloned into M13/pUC-based ... T3 RNA polymerase promoters, or lambda gt10 ... a concentration of 0.1 µg/µl in water. ... sequencing reactions using SequiTherm™ EXCEL™ II DNA ...
Biology Products: